SciGen Pte Ltd.

<p><strong>4.1 Therapeutic indications</strong></p> <p>Reversal of neuromuscular blockade induced by rocuronium or vecuronium in patients 2 years of age and older.</p>

<p><strong>INDICATIONS</strong></p> <ul> <li>Treatment of osteolytic, osteoblastic, and mixed bone metastases of solid tumours and osteolytic lesions of multiple myeloma, in conjunction with standard antineoplastic therapy.</li> <li>Treatment of hypercalcemia of malignancy (HCM).</li> </ul>

<p><strong>4.1 Therapeutic indications</strong><br> <u>Children</u><br> Growth disturbance due to insufficient secretion of growth hormone (growth hormone deficiency, GHD).<br> Growth disturbance associated with Turner syndrome.</p> <p><u>Adults</u><br> Replacement therapy in adults with pronounced growth hormone deficiency. Patients with severe growth hormone deficiency in adulthood are defined as patients with known hypothalamic pituitary pathology and at least one known deficiency of pituitary hormone not being prolactin. These patients should undergo a single dynamic test in order to diagnose or exclude a growth hormone deficiency. In patients with childhood onset isolated GH deficiency (no evidence of hypothalamic-pituitary disease or cranial irradiation), two dynamic tests should be recommended, except for those having low IGF-I concentrations (SDS &lt; -2) who may be considered for one test. The cut-off point of the dynamic test should be strict.</p>

<p><strong>4.1 Therapeutic indications</strong><br> <u>Children</u><br> Growth disturbance due to insufficient secretion of growth hormone (growth hormone deficiency, GHD).<br> Growth disturbance associated with Turner syndrome.</p> <p><u>Adults</u><br> Replacement therapy in adults with pronounced growth hormone deficiency. Patients with severe growth hormone deficiency in adulthood are defined as patients with known hypothalamic pituitary pathology and at least one known deficiency of pituitary hormone not being prolactin. These patients should undergo a single dynamic test in order to diagnose or exclude a growth hormone deficiency. In patients with childhood onset isolated GH deficiency (no evidence of hypothalamic-pituitary disease or cranial irradiation), two dynamic tests should be recommended, except for those having low IGF-I concentrations (SDS &lt; -2) who may be considered for one test. The cut-off point of the dynamic test should be strict.</p>

<p><strong>INDICATIONS</strong></p> <ul> <li>Treatment of osteolytic, osteoblastic, and mixed bone metastases of solid tumours and osteolytic lesions of multiple myeloma, in conjunction with standard antineoplastic therapy.</li> <li>Treatment of hypercalcemia of malignancy (HCM).</li> </ul>